Abstract
Background: We describe the phenomenon of crossed cerebellar diaschisis (CCD) in four subjects diagnosed with Alzheimer’s disease (AD) according to the National Institute on Aging - Alzheimer Association (NIA-AA) criteria, in combination with 18F-FDG PET and 11C-PiB PET imaging.
Methods: 18F-FDG PET showed a pattern of cerebral metabolism with relative decrease most prominent in the frontal-parietal cortex of the left hemisphere and crossed hypometabolism of the right cerebellum. 11C-PiB PET showed symmetrical amyloid accumulation, but a lower relative tracer delivery (a surrogate of relative cerebral blood flow) in the left hemisphere. CCD is the phenomenon of unilateral cerebellar hypometabolism as a remote effect of supratentorial dysfunction of the brain in the contralateral hemisphere. The mechanism implies the involvement of the cortico-ponto-cerebellar fibers. The pathophysiology is thought to have a functional or reversible basis but can also reflect in secondary morphologic change. CCD is a well-recognized phenomenon, since the development of new imaging techniques, although scarcely described in neurodegenerative dementias.
Results: To our knowledge this is the first report describing CCD in AD subjects with documentation of both 18F-FDG PET and 11C-PiB PET imaging. CCD in our subjects was explained on a functional basis due to neurodegenerative pathology in the left hemisphere. There was no structural lesion and the symmetric amyloid accumulation did not correspond with the unilateral metabolic impairment.
Conclusion: This suggests that CCD might be caused by non-amyloid neurodegeneration. The pathophysiological mechanism, clinical relevance and therapeutic implications of CCD and the role of the cerebellum in AD need further investigation.
Keywords: Cerebellar diaschisis (CCD), hypometabolism, supratentorial lesions, contralateral, dementia, Alzheimer's disease.
Current Alzheimer Research
Title:Crossed Cerebellar Diaschisis in Alzheimer’s Disease
Volume: 15 Issue: 13
Author(s): F.E. Reesink*, D. Vállez García, C.A. Sánchez-Catasús, D.E. Peretti, A.T. Willemsen, R. Boellaard, S.K. Meles, R.B. Huitema, B.M. de Jong, R.A. Dierckx and P.P. De Deyn
Affiliation:
- Department of Neurology, Alzheimer Research Center, University of Groningen, University Medical Center, Groningen,Netherlands
Keywords: Cerebellar diaschisis (CCD), hypometabolism, supratentorial lesions, contralateral, dementia, Alzheimer's disease.
Abstract: Background: We describe the phenomenon of crossed cerebellar diaschisis (CCD) in four subjects diagnosed with Alzheimer’s disease (AD) according to the National Institute on Aging - Alzheimer Association (NIA-AA) criteria, in combination with 18F-FDG PET and 11C-PiB PET imaging.
Methods: 18F-FDG PET showed a pattern of cerebral metabolism with relative decrease most prominent in the frontal-parietal cortex of the left hemisphere and crossed hypometabolism of the right cerebellum. 11C-PiB PET showed symmetrical amyloid accumulation, but a lower relative tracer delivery (a surrogate of relative cerebral blood flow) in the left hemisphere. CCD is the phenomenon of unilateral cerebellar hypometabolism as a remote effect of supratentorial dysfunction of the brain in the contralateral hemisphere. The mechanism implies the involvement of the cortico-ponto-cerebellar fibers. The pathophysiology is thought to have a functional or reversible basis but can also reflect in secondary morphologic change. CCD is a well-recognized phenomenon, since the development of new imaging techniques, although scarcely described in neurodegenerative dementias.
Results: To our knowledge this is the first report describing CCD in AD subjects with documentation of both 18F-FDG PET and 11C-PiB PET imaging. CCD in our subjects was explained on a functional basis due to neurodegenerative pathology in the left hemisphere. There was no structural lesion and the symmetric amyloid accumulation did not correspond with the unilateral metabolic impairment.
Conclusion: This suggests that CCD might be caused by non-amyloid neurodegeneration. The pathophysiological mechanism, clinical relevance and therapeutic implications of CCD and the role of the cerebellum in AD need further investigation.
Export Options
About this article
Cite this article as:
Reesink F.E.*, García Vállez D. , Sánchez-Catasús C.A., Peretti D.E., Willemsen A.T., Boellaard R. , Meles S.K., Huitema R.B., de Jong B.M., Dierckx R.A. and De Deyn P.P. , Crossed Cerebellar Diaschisis in Alzheimer’s Disease, Current Alzheimer Research 2018; 15 (13) . https://dx.doi.org/10.2174/1567205015666180913102615
DOI https://dx.doi.org/10.2174/1567205015666180913102615 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Effect of the Interaction Between Hypertension and Cerebral White Matter Changes on the Progression of Alzheimer Disease
Current Alzheimer Research Cardiovascular Risk, Inflammation and Physical Activity in Rheumatoid Arthritis
Current Rheumatology Reviews Heart Failure in North America
Current Cardiology Reviews VIP in Neurological Diseases: More Than A Neuropeptide
Endocrine, Metabolic & Immune Disorders - Drug Targets The Path from Anti Parkinson Drug Selegiline and Rasagiline to Multifunctional Neuroprotective Anti Alzheimer Drugs Ladostigil and M30
Current Alzheimer Research Electrochemistry of Alzheimer Disease Amyloid Beta Peptides
Current Medicinal Chemistry Side Effects of AAS Abuse: An Overview
Mini-Reviews in Medicinal Chemistry Novel Risk Factors Related to Stable Angina
Current Pharmaceutical Design Acetylcholine Receptors and Tau Phosphorylation
Current Molecular Medicine Endocannabinoid System in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) The Axis of Thrombospondin-1, Transforming Growth Factor Beta and Connective Tissue Growth Factor: An Emerging Therapeutic Target in Rheumatoid Arthritis
Current Vascular Pharmacology Neurotrophins - From Pathophysiology to Treatment in Alzheimers Disease
Current Alzheimer Research Mass Spectrometry Techniques: Principles and Practices for Quantitative Proteomics
Current Protein & Peptide Science Default Mode, Executive Function, and Language Functional Connectivity Networks are Compromised in Mild Alzheimer´s Disease
Current Alzheimer Research Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research Aging Liver: Can Exercise be a Better Way to Delay the Process than Nutritional and Pharmacological Intervention? Focus on Lipid Metabolism
Current Pharmaceutical Design Cardiovascular Disease in Diabetes
Mini-Reviews in Medicinal Chemistry Psychobiological Model of Personality: Guidelines for Pharmacotherapy of Personality Disorder
Current Psychopharmacology The Role of Lipids and Membranes in the Pathogenesis of Alzheimer's Disease: A Comprehensive View
Current Alzheimer Research Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets